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OBJECTIVE—Pancreatic -cells exposed to proinflammatory
cytokines display alterations in gene expression resulting in
defective insulin secretion and apoptosis. MicroRNAs are small
noncoding RNAs emerging as key regulators of gene expression.
Here, we evaluated the contribution of microRNAs to cytokine-
mediated -cell cytotoxicity.
RESEARCH DESIGN AND METHODS—We used global mi-
croarray profiling and real-time PCR analysis to detect changes in
microRNA expression in -cells exposed to cytokines and in
islets of pre-diabetic NOD mice. We assessed the involvement of
the microRNAs affected in cytokine-mediated -cell failure by
modifying their expression in insulin-secreting MIN6 cells.
RESULTS—We found that IL-1 and TNF- induce the expres-
sion of miR-21, miR-34a, and miR-146a both in MIN6 cells and
human pancreatic islets. We further show an increase of these
microRNAs in islets of NOD mice during development of pre-
diabetic insulitis. Blocking miR-21, miR-34a, or miR-146a func-
tion using antisense molecules did not restore insulin-promoter
activity but prevented the reduction in glucose-induced insulin
secretion observed upon IL-1 exposure. Moreover, anti–miR-
34a and anti–miR-146a treatment protected MIN6 cells from
cytokine-triggered cell death.
CONCLUSIONS—Our data identify miR-21, miR-34a, and miR-
146a as novel players in -cell failure elicited in vitro and in vivo
by proinflammatory cytokines, notably during the development
of peri-insulitis that precedes overt diabetes in NOD mice.
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Insulin release from pancreatic -cells is essential forblood glucose homeostasis. Diabetes develops if theamount of insulin released by -cells is insufficientto cover the metabolic demand. Type 1 diabetes is
an autoimmune disease characterized by an inflammatory
response against pancreatic islets, leading to selective
and progressive -cell loss (1). Type 2 diabetes, the most
common form of the disease, is often associated with
obesity and results from defects in insulin secretion or
from diminished sensitivity of target tissues to insulin
action (2). Although the etiology differs from that of type 1
diabetes, immune-cell infiltration and decrease in func-
tional -cell mass are also observed in type 2 diabetes (3).
Proinflammatory cytokines such as interleukin (IL)-1,
tumor necrosis factor (TNF)-, and -interferon (IFN-),
produced by infiltrating leukocytes and by islet cells, play
a central role in -cell failure and in the development of
diabetes (1,3–5). Prolonged exposure to cytokines leads to
decreased capacity of -cells to produce and release
insulin in response to secretagogues and, in the long term,
to destruction of the cells by apoptosis or necrosis. Thus,
the elucidation of the molecular events occurring during
immune-mediated injury is essential to determine the
causes of diabetes and develop new treatments for the
disease.
Cytokines induce modifications in gene expression
through the activation of different transcription factors
(1,3) that lead to upregulation of proteins exerting harmful
actions on -cells (6,7). In addition to transcription fac-
tors, other regulatory molecules make an important con-
tribution to the control of gene expression (8). Eukaryotic
cells contain hundreds of noncoding RNAs called microR-
NAs (miRNAs) that associate with the 3 untranslated
region of mRNAs (9), potentially inhibiting messenger
translation of thousands of genes (10,11). Although we are
only beginning to appreciate the potential of miRNAs as
controllers of gene networks, there is already evidence
that these molecules play a central role in many physio-
logical processes and human diseases (12). miRNAs are
also important regulators of specialized -cell functions
(13–16). Indeed, expression of appropriate levels of miR-
375, miR-9, and miR-124a are required for insulin biosyn-
thesis and for optimal release of the hormone in response
to secretagogues (13–16).
The aim of this study was to investigate the possible
involvement of miRNAs in cytokine-mediated -cell dam-
age and in the development of type 1 diabetes. We found
that proinflammatory cytokines induce the expression of a
subset of miRNAs, which alters insulin secretion and
promotes -cell apoptosis.
RESEARCH DESIGN AND METHODS
Insulin-secreting cell line culture and pancreatic islet isolation. The
insulin-secreting cell line MIN6B1 and INS-1E were cultured as described
(17,18). Transfections of MIN6 and INS-1E cells were performed with Lipo-
fectamine 2000 (Invitrogen, Carlsbad, CA) using 60 pmol oligonucleotides.
Human pancreatic islets were provided by the Cell Isolation and Trans-
plantation Center (University of Geneva) thanks to the ECIT “Islets for
Research” distribution program sponsored by the Juvenile Diabetes Research
Foundation and were cultured for 4 days in CMRL medium. Female NOD mice
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were obtained from The Jackson Laboratories (Bar Harbor, ME). Mouse
pancreatic islets were isolated by collagenase digestion (19). After isolation,
the islets were immediately processed for RNA purification and histological
analysis.
Evaluation of islet lymphocytes. Islets isolated from NOD mice were fixed
and sectioned at 1 m thickness as previously described (20). The number of
-cells and lymphocytes was scored on 5–17 sections taken at 30-m intervals.
A minimum of 10 lymphocytes per islet was considered the threshold for the
presence of peri- (lymphocytes around the islet) or intrainsulitis (lymphocytes
within the islet). Given that the islets with such alterations were not
distributed in a Gaussian way, values were expressed as medians and
compared with the median test as provided by the Statistical Package for
Social Sciences (SPSS, Chicago, IL). -cell numbers were expressed as
means  SEM and compared with the ANOVA test, provided by the same
software.
miRNA profiling. Total RNA from MIN6 cells treated for 24 h with either 10
ng/ml IL-1 or 10 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN- was
extracted using the mirVana miRNA Isolation Kit (Ambion, Austin, TX).
Global miRNA profiling was performed by the LC Sciences microarray service
(Houston, TX). The service included the analysis of the level of all mouse
miRNAs available on the miRBase, version 9.2. Expression analysis was
performed on a microarray platform using the Paraflo microfluidic chip
technology (21).
miRNA detection, overexpression, and downregulation. RNA extraction
for miRNA analysis was performed with the mirVana isolation kit. Mature
miRNA measurements were performed using a quantitative RT-PCR (qRT-
PCR) miRNA Detection kit (Ambion). The results were normalized using
cDNAs amplified with U6 primers in the same samples. To increase miRNA
levels, the cells were transfected with RNA duplexes (Eurogentec, Seraing,
Belgium) corresponding with the mature sequence of the noncoding RNA. A
siRNA duplex directed against green fluorescent protein was used as a
control. Endogenous activity of miRNAs was blocked by transfecting the
corresponding clear-MiR miRNA inhibitor (Eurogentec, Seraing, Belgium).
Analysis of the expression of protein-coding genes. RNA extraction was
performed with the RNAqueous isolation kit (Ambion). Conventional qRT-
PCR was carried out as previously described (22).
Luciferase assays. The luciferase reporter plasmid driven by the miR-146a
promoter and the corresponding construct in which the nuclear factor-B
(NF-B) binding sites are mutated (23) were provided by Dr. D. Baltimore
(California Institute of Technology, Pasadena, CA). The luciferase reporter
plasmid driven by a 600-bp fragment of the rat insulin 2 promoter has
previously been described (24). Luciferase activity was measured with a
dual-luciferase reporter assay (Promega, Madison, WI) 2 days after transfec-
tion. Firefly luciferase activity was normalized for transfection efficiency
with the SV40-driven Renilla activity generated by the psiCHECK-1 vector
(Promega).
Secretion assay. MIN6 cells were transfected with RNA duplexes or anti-
sense oligonucleotides. After 48 h, the cells were preincubated for 30 min in
KREBS buffer containing 2 mmol/l glucose (25). The medium was then
discarded, and the cells were incubated for 45 min in the same buffer (basal
condition) or in a KREBS buffer containing 20 mmol/l glucose (stimulatory
condition). The amount of insulin in the samples was assessed by ELISA
(SPI-bio, Montigny-le-Bretonneux, France).
Western blots. Protein extracts were separated on acrylamide gels and
transferred on polyvinylidine fluoride membranes, and immunoreactive bands
were visualized by chemiluminescence (Amersham Biosciences). Antibodies
against vesicle-associated membrane protein (VAMP)2 and Rab3a were pur-
chased from Synaptic Systems (Goettingen, Germany). The antibody against
syntaxin1a was bought from Sigma-Aldrich (St. Louis, MO) and that against
actin from Chemicon International (Temecula, CA). Antibodies against c-Jun
and BclII were from Cell Signaling (Danvers, MA) and those against phos-
phorylated c-Jun (Ser73) and TNF receptor–associated factor (TRAF)6 from
Upstate Biotechnology (Temencula, CA). The antibody against IL-1 receptor–
associated kinase (IRAK)1 was bought from Abcam (Cambridge, U.K.).
Cell death. We scored the cells displaying pycnotic nuclei upon Hoechst
33342 staining (25). The experiment was carried out blindly, and at least 500
cells per condition were analyzed. Alternatively, apoptosis was assessed by
enzyme-linked immunoassay using a Cell Death Detection kit (Roche, Rot-
kreuz, Switzerland).
Statistical analysis. Statistical differences were tested by ANOVA. The
experiments including more than two groups were first analyzed by ANOVA,
and multiple comparisons of the means were then carried out using the post
hoc Dunnett’s test, with a discriminating P value of 0.05 (SAS statistical
package; SAS, Carry, NC).
RESULTS
To investigate the possible involvement of miRNAs in
cytokine-induced -cell failure, the mouse insulin-secret-
ing cell line MIN6 was incubated for 24 h in the presence
of 10 ng/ml IL-1 or of a mix of 10 ng/ml IL-1, 10 ng/ml
TNF-, and 10 ng/ml IFN-. Global miRNA expression
profile was then determined by microarray analyses. The
majority of the miRNAs was not affected by cytokine
treatment (supplementary Table 1, available in an online
appendix [http://diabetes.diabetesjournals.org/cgi/content/
full/db09-0881/DC1]). However, miR-21, miR-34a, and miR-
146a/b were significantly increased both by IL-1 and the
cytokine mix. These findings were confirmed by qRT-PCR
of MIN6 cells and isolated human pancreatic islets (Fig. 1),
and similar results were also obtained with the rat insulin-
secreting cell line INS-1E (supplementary Fig. 1). In one of
the samples used for microarray analysis, we observed
changes in miR-96 expression. However, the levels of
miR-96 measured by qRT-PCR in four other independent
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FIG. 1. Effect of IL-1 and of a mix of cytokines on the expression of
miR-21, miR-34a, and miR-146a. Left panel: MIN6 cells were incubated
for 24 h with 10 ng/ml IL-1 or with a mix of 10 ng/ml IL-1, 10 ng/ml
TNF-, and 10 ng/ml IFN-. The expression of the indicated miRNAs
was assessed by quantitative RT-PCR. The results are expressed as
percent of the level of U6, which was measured in parallel in the same
samples. They are the means SEM of three independent experiments.
*Conditions that are significantly different from controls (P < 0.05).
Right panel: Isolated human pancreatic islets were incubated for 24 h
in the presence or absence of 10 ng/ml IL-1. The expression of the
indicated miRNAs was assessed by quantitative RT-PCR and is ex-
pressed as percent of the level of the corresponding miRNA in control
islets. Data are shown as means  SEM of four independent experi-
ments. *Conditions significantly different from controls (P < 0.05; n 
4). Cyto, cytokine.
E. ROGGLI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 979
experiments represented 102  11 and 104  17% of those
of controls in MIN6 cells treated with IL-1 and cytokine
mix, respectively. Therefore, the role of this miRNA was
not further investigated.
The induction of miR-146a (primers are not available for
the selective detection of miR-146b by qRT-PCR) was
detectable already after 6 h incubation with IL-1, reached
its maximum after 24 h, and remained stable until 72 h
(supplementary Fig. 2). miR-21 and miR-34a expression
was significantly higher than control cells only after 24 h
incubation, and these miRNAs were not further increased
after 48 or 72 h. Half-maximal induction of the three
miRNAs was observed at 0.1 ng/ml IL-1, while maximal
effect was achieved with 1 ng/ml (supplementary Fig. 3).
Incubation of MIN6 cells with different combinations of
cytokines revealed that IL-1 was, alone, the most potent
inducer of miR-21 and miR-146a expression (Fig. 2). The
level of these miRNAs was also increased by TNF- but
not by IFN-. The expression of miR-34a was stimulated to
approximately the same extent by IL-1 and TNF-,
whereas IFN- again had no effect (Fig. 2).
We then tested whether the development of diabetes in
NOD mice, a well-established type 1 diabetes model (26),
is preceded by changes in the level of miRNAs in pancre-
atic islets. In NOD mice, peri-insulitis begins around a few
islets 6–8 weeks after birth and characterizes a majority of
islets at the age of 13–14 weeks (27). At that time, the
-cell mass begins to decrease, resulting in elevation of
blood glucose and development of diabetes. We measured
miRNA expression in islets from female NOD mice at the
ages of 4, 8, and 13 weeks displaying blood glucose levels
within the normal range (Fig. 3). In islets from 8- and
13-week-old animals, the levels of miR-21 and miR-146a
were significantly higher compared with those from
0.02
0.04
0.06
0.08
0.10
0.12
%
 o
f U
6 
ex
pr
es
si
on
miR-34a
miR-146a
0.5
1.0
1.5
2.0
2.5
3.0
3.5
%
 o
f U
6 
ex
pr
es
si
on
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
%
 o
f U
6 
ex
pr
es
si
on
Ctrl IL1β TNFα IFNγ TNFα
+IFNγ
Cyto
Mix
Ctrl IL1β TNFα IFNγ TNFα
+IFNγ
Cyto
Mix
Ctrl IL1β TNFα IFNγ TNFα
+IFNγ
Cyto
Mix
miR-21
*
*
* *
*
*
*
*
*
*
*
*
FIG. 2. Effect of different cytokine combinations on the expression of
miR-21, miR-34a, and miR-146a. MIN6 cells were incubated in the
presence of the indicated cytokines (10 ng/ml) for 24 h. The expression
of miR-21 (A), miR-34a (B), and miR-146a (C) was assessed by
quantitative RT-PCR. The results are expressed as percent of the level
of U6 that was measured in parallel in the same samples. Data are
shown as means SEM of three independent experiments. *Conditions
that are significantly different from controls (P < 0.05). Cyto,
cytokine.
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FIG. 3. Expression of miR-21, miR-34a, and miR-146a in pancreatic
islets of NOD mice. Pancreatic islets were isolated from female NOD
mice of different ages. Only animals displaying blood glucose levels
within the normal range were included in the study. Blood glucose
levels for the mice included in the study were as follows: 99  5 mg/dl
for 4-week-old mice (n 4), 100 8 mg/dl for 8-week-old mice (n 4),
and 132  25 mg/dl for 13-week-old mice (n  9). The levels of miR-21,
miR-34a, and miR-146a were measured by quantitative RT-PCR and are
given as % of U6 expression. Data are shown as means  SEM of four
independent experiments. *Conditions that are significantly different
from controls (P < 0.05).
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4-week-old mice (Fig. 3). miR-34a was also increased to a
lesser extent in 8- and 13-week-old mice. In contrast, the
level of miR-7, a miRNA selectively expressed in pancre-
atic islet cells (28), was not significantly altered (not
shown). Evaluation of sections of islets, isolated like those
extracted for quantitive PCR, showed that islets from
4-week-old animals contain very few lymphocytes. A ma-
jority of the islets isolated from 8-week-old NOD mice had
small-to-moderate peri-insulitis, with a lower proportion
of the islets also containing sufficient lymphocyte numbers
to be scored for intra-islet insulitis (supplementary Fig. 4).
The same phenotypes were seen in the islets isolated from
normoglycemic, 14-week-old NOD mice in which the pro-
portion of islets with intraislet insulitis and the numbers of
lymphocytes per islet tended to increase, whereas -cells
tended to decrease (supplementary Fig. 4). However, a
sizable proportion of islets of both 8- and 14-week-old
animals did not display signs of insulitis, and those that did
still featured relatively few intraislet lymphocytes (supple-
mentary Fig. 4). These data document that the islets we
isolated closely reflected the distribution of islets exam-
ined within the intact pancreas of NOD mice (data not
shown).
In other cell systems, miR-146a is induced by the
activation of the NF-B pathway (23). Exposure of MIN6
cells to cytokines led to an increase in the expression of a
luciferase reporter construct driven by the miR-146a pro-
moter (Fig. 4). Mutation of the NF-B binding sites in the
miR-146a promoter (23) abolished this effect (Fig. 4),
indicating that the cytokine-mediated induction of miR-
146a in insulin-secreting cells results from NF-B activa-
tion. Basal promoter activity was also reduced by
mutation of the putative NF-B binding sites (Fig. 4),
suggesting a contribution of this transcription factor to the
expression of miR-146a under resting conditions as well.
Next, we examined whether changes in the level of the
three miRNAs induced by cytokines altered specific -cell
functions. Overexpression of miRNAs was achieved by
transfection of RNA duplexes corresponding to the mature
form of the miRNAs. Reduction of miRNA activities was
obtained by transfecting antisense O-methyl RNA oligonu-
cleotides (29). To verify the efficacy of this approach, the
miRNAs and the anti-miRs were cotransfected with lucif-
erase constructs containing specific miRNA binding sites in
their 3 untranslated region (UTR) (miRNA sensors). Over-
expression of each miRNA led to a strong reduction in the
luciferase activity of the corresponding sensor, whereas this
activity was increased upon blockade of endogenous miRNA
function by anti-miRs (supplementary Fig. 5).
We first assessed the impact of the three miRNAs on
insulin gene expression. Overexpression of miR-21 or
miR-146a did not significantly affect insulin content (Fig.
5A), insulin promoter activity (Fig. 5C), or proinsulin
mRNA levels (not shown). In contrast, miR-34a overex-
pression led to a small decrease in insulin content (Fig.
5A) and insulin promoter activity (Fig. 5C), accompanied
by a reduction in proinsulin mRNA level (Fig. 5B). As
expected, incubation of MIN6 cells with IL-1 led to a
dose-dependent impairment in the activity of the insulin
promoter (Fig. 5D) and to a decrease in proinsulin mRNA
content (Fig. 5E). Treatment of the cells with anti–miR-34a
did not prevent the decrease in the activity of the insulin
promoter (Fig. 5D) or proinsulin mRNA levels (Fig. 5E),
suggesting that miR-34a does not contribute to these
effects of the cytokine. Anti–miR-21 and anti–miR-146a
were also unable to restore insulin biosynthesis in IL-1–
treated cells (not shown).
We then tested whether the level of the three miRNAs
can influence the secretory capacity of the cells. Overex-
pression of miR-34a and miR-21 did not affect basal
secretion but reduced maximal, glucose-induced insulin
release (Fig. 6A). miR-146a overexpression had no signif-
icant effect on insulin secretion (Fig. 6A). These observa-
tions cannot be merely attributed to changes in the
number of cells/well. Indeed, the total amount of proteins/
well was not significantly different between experimental
conditions (data not shown). The defect in secretion
observed in the presence of elevated levels of miR-21 and
miR-34a was accompanied by a drop in the expression of
VAMP2, a sensitive factor attachment protein receptor
(SNARE) protein that is essential for -cell exocytosis
(30–32), and of the GTPase Rab3a (33) (Fig. 6B). Incuba-
tion of MIN6 cells for 24 h in the presence of 1 ng/ml IL-1,
a condition that alone does not significantly affect cell
survival (data not shown), resulted in impaired glucose-
induced insulin secretion (Fig. 6C). Defective insulin se-
cretion was accompanied by a reduction in the expression
of VAMP2 and Rab3a (Fig. 6B). Pretreatment of the cells
exposed to 1 ng/ml IL-1 with anti–miR-21 or anti–miR-34a
prevented the decrease of VAMP2 but not of Rab3a (Fig.
6B) and improved glucose-induced secretion in cytokine-
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FIG. 4. The expression of miR-146a is controlled by the NF-B pathway.
Upper panel: MIN6 cells were transiently cotransfected with a plasmid
leading to constitutive expression of Renilla luciferase and with Firefly
luciferase reporter constructs driven either by the wild-type miR-146a
promoter (promo miR-146 wt) or by a promoter lacking the putative
NF-B binding sites (promo miR-146 mutant). The cells were then
treated either for 6 or 48 h with 10 ng/ml IL-1. The figure shows a
representative experiment out of five and presents the ratio between
the Firefly and Renilla luciferase activities measured at the end of the
IL-1 treatment. Lower panel: The same experiment as in the upper
panel, except that the cells were treated with a mixture of cytokines
(10 ng/ml IL-1, 10 ng/ml TNF-, and 10 ng/ml IFN-). Cyt, cytokine.
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FIG. 5. Effect of miR-21, miR-34a, and miR-146a on insulin-promoter
activity and insulin biosynthesis. A: MIN6 cells were transfected with a
control RNA duplex (open bars) or with duplexes containing the
mature forms of miR-21, miR-34a, or miR-146a (gray bars). Insulin
content was measured 2 days later by ELISA. The results are expressed
as percent of the values in control cells. B: Proinsulin and glyceralde-
hyde-3-phosphate dehydrogenase (GAPHD) mRNA levels in control
MIN6 cells and in cells overexpressing miR-34a were assessed by
quantitative RT-PCR. The results are expressed as the ratios between
proinsulin and glyceraldehyde-3-phosphate dehydrogenase mRNA. C:
MIN6 cells were transiently cotransfected with a Firefly luciferase
reporter construct driven by the rat insulin promoter, a plasmid
leading to constitutive expression of Renilla luciferase and RNA
duplexes containing the indicated mature miRNAs. Luciferase activi-
ties were measured 2 days later. The results are expressed as the ratios
between Firefly and Renilla luciferases. D: MIN6 cells were transiently
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bars) or with anti-34a (black bars). The day after, the cells were
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ng/ml IL-1. Proinsulin mRNA levels were determined by quantitative
RT-PCR. The results are expressed as percent of the level of proinsulin
mRNA in untreated control cells. All data are shown as means  SEM
of three (B and E), four (C and D), or eight (A) independent experi-
ments. *Conditions that are significantly different from controls (P <
0.05).
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FIG. 6. Involvement of miR-21, miR-34a, and miR-146a in insulin secre-
tion. A: MIN6 cells were transiently transfected with RNA duplexes
containing the mature sequence of the indicated miRNAs. Control cells
were transfected with a siRNA duplex against green fluorescent protein.
Two days later, the cells were preincubated for 30 min in Krebs-Ringer
buffer containing 2 mmol/l glucose and successively incubated either in
the same buffer (white bars) or in Krebs-Ringer buffer containing 20
mmol/l glucose (gray bars). The amount of insulin released during the
incubation period was measured by ELISA. The results are the means 
SEM of three independent experiments. *Significantly different (P <
0.05) from control. B: MIN6 cells were transiently transfected with RNA
duplexes leading to the overexpression of miR-21 or miR-34a. The expres-
sion of the indicated components of the machinery governing insulin
exocytosis was analyzed by Western blotting (left panels). MIN6 cells
were transiently transfected with a control oligonucleotide (control) or
with O-methyl antisense oligonucleotides blocking the activity of miR-21
or miR-34a (anti-21 and anti-34a, respectively). The day after, the cells
were incubated with or without IL-1 for 24 h. The expression of the
indicated proteins was analyzed by Western blotting (right panel). The
figure shows the results of a representative experiment out of three. C:
MIN6 cells were transfected with the indicated anti-miRs. The day after,
they were incubated for 24 h with () or without () IL-1 (1 ng/ml).
Insulin release in the presence of 2 and 20 mmol/l glucose was assessed by
ELISA. The results are the means  SEM of five independent experi-
ments. *High glucose conditions that are significantly different from
control cells incubated in the presence of IL-1 (P < 0.05).
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treated cells (Fig. 6C). Interestingly, although alone overex-
pression of miR-146a did not affect glucose-induced insulin
release (Fig. 6A), anti–miR-146 pretreatment was able to
alleviate the secretory defect elicited by IL-1 (Fig. 6C).
Prolonged exposure of -cells to cytokines sensitizes
them to apoptosis (1,3,5). Overexpression of miR-34a or
miR-146a increased the number of cells undergoing apo-
ptosis, whereas overexpression of miR-21 had no signifi-
cant effect (Fig. 7A). In agreement with previously
published data (34), anti–miR-21 treatment led to an
increase in apoptosis (Fig. 7B). In contrast, reducing
miR-34a or miR-146a levels did not affect cell survival.
Treatment of the cells with anti–miR-34a or anti–miR-146
diminished the number of dying cells in the presence of
high doses of IL-1 (10 ng/ml) (Fig. 7C) or the cytokine
mix (data not shown). Similar results were obtained when
apoptosis was assessed specifically using an alternative
method (supplementary Fig. 6).
We have previously shown that the protective effect of
anti–miR-34a on apoptosis may be due to the capacity of
miR-34a to control the expression of the antiapoptotic
protein BclII (25). Indeed, overexpression of miR-34a led
to a decrease in BclII and anti–miR-34a raised the level of
the antiapoptotic protein in the presence of IL-1 (supple-
mentary Fig. 7), potentially explaining part of the protec-
tive effect of the anti-miR. The mode of action of miR-146a,
the miRNA displaying the most dramatic expression
changes in response to cytokines, is presently unknown. In
other cell systems, miR-146a controls the expression of
IRAK1 and TRAF6. Overexpression of miR-146a in MIN6
cells caused a decrease in IRAK1 and TRAF6, whereas
blockade of miR-146a raised the level of these two compo-
nents of IL-1 signaling (supplementary Fig. 8). Although
these findings confirm the capacity of miR-146a to modulate
IL-1 signaling, they are unlikely to account for the protective
effects of anti–miR-146. However, we discovered that the
induction of c-Jun expression elicited by IL-1 is reduced in
cells lacking miR-146a. In these cells, the sixfold increase in
c-Jun mRNA observed upon 1 h incubation with IL-1 was
reduced by 38 4% (n	 3) (data not shown). Moreover, the
total amount of c-Jun and the phosphorylated fraction of the
transcription factor present in IL-1-treated cells were re-
duced by 
60% (Fig. 8).
DISCUSSION
During development of type 1 diabetes, pancreatic -cells are
exposed to proinflammatory cytokines produced by invading
leukocytes and by the islet cells themselves. Chronic expo-
sure to these inflammatory mediators results in changes in
gene expression culminating in the loss of -cell functions
and apoptosis (6,8,35). miRNAs are emerging as important
regulators of gene expression, but their involvement in
cytokine-mediated -cell failure has not been evaluated.
In this study, we identified three miRNAs that are induced in
cytokine-treated -cells and in pre-diabetic NOD mice. The
increase in miRNAs observed in NOD mice between 4 and 8
weeks of age cannot be attributed to immune cells carried
out during the isolation procedure, given that at the latter
time point, these cells were still quite rare in most islets. In
the islets isolated from normoglycemic 14-week-old NOD
mice, an increasing number of lymphocytes surrounded the
islets showing insulitis, but these cells were still outnum-
bered by -cells and did not express detectable levels of the
three miRNAs, as evaluated by in situ hybridization (data not
shown). Moreover, the level of miR-21 and miR-34a is higher
in islets than immune tissues, and that of miR-146a is only
two to three times lower (supplementary Fig. 9). Although
we cannot exclude that the immune cells surrounding the
islets express miRNA levels different from those in spleen
and thymus, these findings make it very unlikely that lym-
phocyte infiltration is the sole determinant of the changes in
miRNA that we observed. Rather, the finding that the same
miRNAs aremodulated by cytokines in insulin-producing cell
lines and islets isolated from nondiabetic donors strongly
suggests that the miRNA changes occurred in islet cells.
Interestingly, prolonged exposure of -cells to palmitate
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and proinflammatory cytokines affects the expression of
an overlapping group of miRNAs, and changes in miR-34a
and miR-146a expression are observed in both type 1
(NOD mice [this study]) and type 2 (db/db mice [25])
diabetes models, suggesting analogies in the mechanisms
leading to -cell failure. In agreement with this hypothesis,
it has been proposed that islet inflammation plays a role in
both type 1 and type 2 diabetes (3).
The most striking changes in the miRNA profile con-
cerned miR-146a. The expression of this miRNA is con-
trolled by NF-B, a transcription factor involved in
cytokine-mediated -cell dysfunction and in the develop-
ment of diabetes. Indeed, overexpression of an NF-B
super-repressor protects -cells against cytokine-induced
apoptosis (36), and transgenic mice expressing the super-
repressor are resistant to diabetes induced by multiple
streptozotocin injections (37). Inhibition of inducible ni-
tric oxide synthase with 1 mmol/l N--nitro-L-arginine
methyl ester did not prevent the induction of miR-146a,
confirming that the miRNA is directly controlled by NF-B
(E.R., A.B., S.G., N.L.-M., A.A., P.M., R.R., unpublished
observations). Blockade of miR-146a improved glucose-
stimulated insulin secretion in IL-1–treated cells and
partially protected the cells against apoptosis triggered by
cytokines. These findings indicate that part of the effects
of the activation of the NF-B pathway in -cells may be
mediated by the induction of miR-146a. Although upregu-
lation and downregulation of the levels of miR-146a elic-
ited opposite effects on -cell death, overexpression of
miR-146a per se was ineffective on insulin secretion. One
possible explanation for this finding is that, under resting
conditions, the transfected miR-146a cannot access all its
potential mRNA targets because the binding sites are
masked by RNA-binding proteins (38,39). Cytokines are
known to affect expression and function of several RNA-
binding proteins (8). Thus, a subset of targets may become
accessible and repressed only upon IL-1 treatment, un-
veiling the role played by miR-146a in the secretory
function of -cells. Another possibility is that the anti-miR
treatment allows for the expression of genes already fully
repressed by miR-146a and that, therefore, cannot be
further reduced by the overexpression of the miRNA.
While sustained activation of NF-B has a deleterious
impact on -cells, transient and moderate activation of
this signaling cascade is required for proper glucose-
stimulated insulin secretion and -cell survival (40,41).
miR-146a is expected to have different affinities for its
numerous targets. Interestingly, TRAF6 and IRAK1, two
key components of the IL-1 and TNF- signaling cascade,
are among the best-predicted targets of miR-146a (10,11),
and repression was experimentally confirmed in this
study. A moderate induction of miR-146a may contribute
to modulation of the response of the cells to these two
cytokines. In contrast, a strong and prolonged induction of
miR-146a in the presence of cytokines may result in the
repression of additional targets with a deleterious impact
on glucose-induced insulin secretion and -cell survival.
The mechanisms behind the contribution of miR-146a to
the adverse effects of cytokines on -cells remain to be
fully elucidated. We found that silencing of miR-146a
attenuates c-Jun induction in IL-1–treated cells without
affecting c-Jun NH2-terminal kinase activity, which possi-
bly explains some of the protective effects of anti–miR-146
(42). This effect could either be caused by modifications in
the level of components controlling the transcriptional
activity of the c-Jun promoter or by changes in the
expression of RNA-binding proteins that govern c-Jun
mRNA stability (43). Each miRNA is known to generate
subtle modifications in the level of hundreds of targets
(44,45). The attenuation of c-Jun induction is likely to
result from the synergistic effect of these changes and
probably not from repression of a single target mRNA.
Thus, future studies should aim at analyzing the global
impact of miR-146a on the proteome and, in particular, on
the expression of key proteins involved in glucose metab-
olism, stimulus-secretion coupling, and apoptosis rather
than attempting to identify individual targets.
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miR-146a. Two days later, some of the cells were treated with 10 ng/ml
IL-1 for 1 h. The total amount of c-Jun present in the cells at the end
of the treatment (c-Jun) and the fraction of the transcription factor in
phosphorylated form (c-Jun-p) were assessed by Western blotting.
Equal loading in each lane was verified using an antibody against
tubulin. B: MIN6 cells were transfected with either control oligonucle-
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presence () or absence () of 10 ng/ml IL-1 for 1 h. Total c-Jun and
phosphorylated c-Jun were detected as above. In this case, the expo-
sure of the film was reduced to prevent its saturation in the lanes
containing the samples treated with IL-1. The figure shows a repre-
sentative experiment out of three. C: Quantification of the expression
of c-Jun and c-Jun-p by densitometric scanning of the films. Data are
shown as means SEM of three independent experiments. *Conditions
that are significantly different from controls (P < 0.05).
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miR-21 is strongly upregulated in cytokine-treated
-cells and in NOD mice during islet inflammation. In
myeloma cells, the expression of miR-21 is induced by IL-6
through a signaling cascade involving the transcription
factor Stat3 (46). Whether a similar mechanism is operat-
ing in -cells exposed to cytokines remains to be estab-
lished. Overexpression of miR-21 in MIN6 cells led to
impairment in insulin secretion stimulated by glucose. A
decrease in the expression of VAMP2, a secretory granule
protein that is essential for insulin exocytosis (30–32),
may contribute to the defect in hormone release in miR-
21–overexpressing cells. miR-21 adds up to the growing
list of miRNAs capable of modulating the expression of
components of the machinery of exocytosis of pancreatic
-cells (14,15). The 3UTR of VAMP2 mRNA does not
contain miR-21 recognition sites (10,11), which suggests
an indirect effect of the miRNA. Blockade of miR-21
restored VAMP2 expression in IL-1–treated cells and
alleviated the impairment in glucose-induced secretion in
IL-1–treated cells, indicating that the induction of this
miRNA can contribute to the effect of the cytokine.
Changes in the expression of VAMP2 are unlikely to
explain all the effects of miR-21, and possible modifica-
tions in the level of other key genes involved in glucose
metabolism and stimulus-secretion coupling should be
further explored.
Overexpression of miR-21 did not affect survival of MIN6
cells, but knockdown of the miRNA promoted apoptosis.
This finding is in agreement with recent reports showing that
miR-21 functions as an oncogene by translationally repress-
ing the tumor suppressor gene programmed cell death 4
(47,48). Indeed, anti–miR-21 treatment of mammary carci-
noma cells increased apoptosis and decreased cell prolifer-
ation (49). A similar mechanism may also operate in MIN6
cells transfected with anti–miR-21.
Among the miRNAs investigated, miR-34a was the one
displaying less variation in cells exposed to cytokines.
However, possibly because of a fine balance between the
level of the miRNA and of its cellular targets, miR-34a
significantly contributed to the cytotoxic effects of the
cytokines. We recently demonstrated that in insulin-se-
creting cells, activation of the p53 pathway induces the
expression of miR-34a (25). The increase of miR-34a
elicited by different cytokines was accompanied by a rise
of p53 expression (data not shown), suggesting that acti-
vation of this transcription factor may be involved in the
induction of this miRNA in response to IL-1 and TNF-.
However, at present the contribution of other important
signaling pathways triggered by these cytokines cannot be
ruled out and will need to be investigated in detail in future
studies.
Because in -cells this miRNA can target important
proteins such as VAMP2 and the antiapoptotic protein
BclII (25), miR-34a could significantly contribute to cyto-
kine-mediated -cell dysfunction. Indeed, anti-miR34a
treatment partially prevented the decrease in the expres-
sion of VAMP2 and BclII and ameliorated glucose-induced
secretion and survival in IL-1–treated cells. Overexpres-
sion of miR-34a reduced insulin promoter activity and
diminished proinsulin mRNA levels and insulin content.
However, the effect was relatively modest compared with
that of IL-1, and blockade of miR-34a did not restore
insulin-promoter activity in cytokine-treated cells. This
suggests only a marginal contribution, if any, of miR-34a to
the deleterious impact of IL-1 on insulin biosynthesis.
We have shown that proinflammatory cytokines elicit
modifications in miRNA expression that impact on -cell
activities. In this study, the functional improvement achieved
by blocking these miRNAs has been evaluated in insulinoma
cells. Attempts were made to perform similar studies in
primary rat -cells using a published siRNA transfection
protocol (50,51). Unfortunately, using this approach, down-
regulation of miRNAs was insufficient (15–20%) (data not
shown) for the investigatation of restoration of -cell func-
tions in cytokine-treated cells. Although the mechanisms
leading to cytokine-mediated dysfunction and apoptosis in
insulin-secreting cell lines are not fundamentally different
from primary -cells (52), the development of methodologies
capable of efficiently modulating miRNA expression in pri-
mary -cells in vitro and, possibly, in vivo are urgently
needed to verify our findings and assess the contribution of
miR-21, miR-34a, and miR-146a in the development of type 1
diabetes. Moreover, proteomic approaches that allow for
large-scale assessment of protein expression (44,45) will be
necessary for investigating in detail the molecular mecha-
nisms underlying the effects of miR-21, miR-34a, and miR-
146a. A global picture of the changes in protein expression
occurring in cytokine-treated -cells in the presence or
absence of these three miRNAs should provide new insights
into the causes of -cell failure underlying the development
of diabetes.
ACKNOWLEDGMENTS
This work was supported by Swiss National Science
Foundation grants 310000-122430 (to P.M.), 310000-121999
(to A.A.), and 3100A0-113421 and 31003A-127254 (to R.R.)
and by grants from the Juvenile Diabetes Research Foun-
dation (1-2007-158) (to P.M.) and the European Union
(FP-7, BETAIMAGE 222980, and IMI [Innovative Medicine
Initiative], IMIDIA [Innovative Medicine Initiative Diabe-
tes], C2008-T7 [to P.M.]).
This study was supported by a grant from CardioMet
Lausanne (to R.R.). No other potential conflicts of interest
relevant to this article were reported.
We thank Dr. D. Baltimore, California Institute of Tech-
nology, California, for supplying the luciferase reporter
plasmids driven by the miR-146a promoter and M. J.
Girardin for the histological analysis of the isolated islets.
REFERENCES
1. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and
beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5:219–226
2. Prentki M, Vischer S, Glennon MC, Regazzi R, Deeney JT, Corkey BE.
Malonyl-CoA and long chain acyl-CoA esters as metabolic coupling factors
in nutrient-induced insulin secretion. J Biol Chem 1992;267:5802–5810
3. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T.
Cytokines and beta-cell biology: from concept to clinical translation.
Endocr Rev 2008;29:334–350
4. McDaniel ML, Kwon G, Hill JR, Marshall CA, Corbett JA. Cytokines and
nitric oxide in islet inflammation and diabetes. Proc Soc Exp Biol Med
1996;211:24–32
5. Pipeleers D, Hoorens A, Marichal-Pipeleers M, Van de Casteele M, Bou-
wens L, Ling Z. Role of pancreatic -cells in the process of -cell death.
Diabetes 2001;50(Suppl. 1):S52–S57
6. Arnush M, Heitmeier MR, Scarim AL, Marino MH, Manning PT, Corbett JA.
IL-1 produced and released endogenously within human islets inhibits beta
cell function. J Clin Invest 1998;102:516–526
7. Corbett JA, Wang JL, Sweetland MA, Lancaster JR Jr, McDaniel ML.
Interleukin 1 beta induces the formation of nitric oxide by beta-cells
purified from rodent islets of Langerhans: evidence for the beta-cell as a
source and site of action of nitric oxide. J Clin Invest 1992;90:2384–2391
8. D’Hertog W, Overbergh L, Lage K, Ferreira GB, Maris M, Gysemans C,
Flamez D, Cardozo AK, Van den Bergh G, Schoofs L, Arckens L, Moreau Y,
Hansen DA, Eizirik DL, Waelkens E, Mathieu C. Proteomics analysis of
cytokine-induced dysfunction and death in insulin-producing INS-1E cells:
E. ROGGLI AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, APRIL 2010 985
new insights into the pathways involved. Mol Cell Proteomics 2007;6:2180–
2199
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004;116:281–297
10. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, MacMenamin
P, da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. Combinatorial
microRNA target predictions. Nat Genet 2005;37:495–500
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005;120:15–20
12. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human
disease. Annu Rev Genomics Hum Genet 2007;8:215–239
13. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, Scharfmann R,
Rutter GA, Van Obberghen E. MicroRNA-124a regulates Foxa2 expression
and intracellular signaling in pancreatic beta-cells lines. J Biol Chem
2007;282:19575–19588
14. Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of
the machinery of exocytosis of insulin-secreting cells by microRNAs. Biol
Chem 2008;389:305–312
15. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F,
Regazzi R. MicroRNA-9 controls the expression of Granuphilin/Slp4 and
the secretory response of insulin-producing cells. J Biol Chem 2006;281:
26932–26942
16. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer
S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M. A pancreatic islet-specific
microRNA regulates insulin secretion. Nature 2004;432:226–230
17. Lilla V, Webb G, Rickenbach K, Maturana A, Steiner DF, Halban PA,
Irminger JC. Differential gene expression in well-regulated and dysregu-
lated pancreatic beta-cell (MIN6) sublines. Endocrinology 2003;144:1368–
1379
18. Merglen A, Theander S, Rubi B, Chaffard G, Wollheim CB, Maechler P.
Glucose sensitivity and metabolism-secretion coupling studied during
two-year continuous culture in INS-1E insulinoma cells. Endocrinology
2004;145:667–678
19. Charollais A, Gjinovci A, Huarte J, Bauquis J, Nadal A, Martin F, Andreu E,
Sanchez-Andres JV, Calabrese A, Bosco D, Soria B, Wollheim CB, Herrera
PL, Meda P. Junctional communication of pancreatic beta cells contributes
to the control of insulin secretion and glucose tolerance. J Clin Invest
2000;106:235–243
20. Charpantier E, Cancela J, Meda P. Beta cells preferentially exchange
cationic molecules via connexin 36 gap junction channels. Diabetologia
2007;50:2332–2341
21. Zhu Q, Hong A, Sheng N, Zhang X, Matejko A, Jun KY, Srivannavit O, Gulari
E, Gao X, Zhou X. microParaflo biochip for nucleic acid and protein
analysis. Methods Mol Biol 2007;382:287–312
22. Plaisance V, Niederhauser G, Azzouz F, Lenain V, Haefliger JA, Waeber G,
Abderrahmani A. The repressor element silencing transcription factor
(REST)-mediated transcriptional repression requires the inhibition of Sp1.
J Biol Chem 2005;280:401–407
23. Taganov KD, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent
induction of microRNA miR-146, an inhibitor targeted to signaling proteins
of innate immune responses. Proc Natl Acad Sci U S A 2006;103:12481–
12486
24. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang
JY, Regazzi R, Widmann C, Waeber G. Human high-density lipoprotein
particles prevent activation of the JNK pathway induced by human
oxidised low-density lipoprotein particles in pancreatic beta cells. Diabe-
tologia 2007;50:1304–1314
25. Lovis P, Roggli E, Laybutt DR, Gattesco S, Yang JY, Widmann C, Abder-
rahmani A, Regazzi R. Alterations in microRNA expression contribute to
fatty acid–induced pancreatic -cell dysfunction. Diabetes 2008;57:2728–
2736
26. Giarratana N, Penna G, Adorini L. Animal models of spontaneous autoim-
mune disease: type 1 diabetes in the nonobese diabetic mouse. Methods
Mol Biol 2007;380:285–311
27. Debussche X, Lormeau B, Boitard C, Toublanc M, Assan R. Course of
pancreatic beta cell destruction in prediabetic NOD mice: a histomorpho-
metric evaluation. Diabete Metab 1994;20:282–290
28. Bravo-Egana V, Rosero S, Molano RD, Pileggi A, Ricordi C, Dominguez-
Bendala J, Pastori RL. Quantitative differential expression analysis reveals
miR-7 as major islet microRNA. Biochem Biophys Res Commun 2008;366:
922–926
29. Meister G, Landthaler M, Dorsett Y, Tuschl T. Sequence-specific inhibition
of microRNA- and siRNA-induced RNA silencing. RNA 2004;10:544–550
30. Regazzi R, Sadoul K, Meda P, Kelly RB, Halban PA, Wollheim CB.
Mutational analysis of VAMP domains implicated in Ca2-induced insulin
exocytosis. Embo J 1996;15:6951–6959
31. Regazzi R, Wollheim CB, Lang J, Theler JM, Rossetto O, Montecucco C,
Sadoul K, Weller U, Palmer M, Thorens B. VAMP-2 and cellubrevin are
expressed in pancreatic beta-cells and are essential for Ca(2)-but not for
GTP gamma S-induced insulin secretion. Embo J 1995;14:2723–2730
32. Wheeler MB, Sheu L, Ghai M, Bouquillon A, Grondin G, Weller U, Beaudoin
AR, Bennett MK, Trimble WS, Gaisano HY. Characterization of SNARE
protein expression in beta cell lines and pancreatic islets. Endocrinology
1996;137:1340–1348
33. Yaekura K, Julyan R, Wicksteed BL, Hays LB, Alarcon C, Sommers S,
Poitout V, Baskin DG, Wang Y, Philipson LH, Rhodes CJ. Insulin secretory
deficiency and glucose intolerance in Rab3A null mice. J Biol Chem
2003;278:9715–9721
34. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic
factor in human glioblastoma cells. Cancer Res 2005;65:6029–6033
35. Cardozo AK, Kruhoffer M, Leeman R, Orntoft T, Eizirik DL. Identification
of novel cytokine-induced genes in pancreatic -cells by high-density
oligonucleotide arrays. Diabetes 2001;50:909–920
36. Ortis F, Pirot P, Naamane N, Kreins AY, Rasschaert J, Moore F, Theatre E,
Verhaeghe C, Magnusson NE, Chariot A, Orntoft TF, Eizirik DL. Induction
of nuclear factor-kappaB and its downstream genes by TNF-alpha and
IL-1beta has a pro-apoptotic role in pancreatic beta cells. Diabetologia
2008;51:1213–1225
37. Eldor R, Yeffet A, Baum K, Doviner V, Amar D, Ben-Neriah Y, Christofori
G, Peled A, Carel JC, Boitard C, Klein T, Serup P, Eizirik DL, Melloul D.
Conditional and specific NF-kappaB blockade protects pancreatic beta
cells from diabetogenic agents. Proc Natl Acad Sci U S A 2006;103:5072–
5077
38. Bhattacharyya SN, Habermacher R, Martine U, Closs EI, Filipowicz W.
Stress-induced reversal of microRNA repression and mRNA P-body local-
ization in human cells. Cold Spring Harb Symp Quant Biol 2006;71:513–521
39. Kedde M, Agami R. Interplay between microRNAs and RNA-binding
proteins determines developmental processes. Cell Cycle 2008;7:899–903
40. Hammar EB, Irminger JC, Rickenbach K, Parnaud G, Ribaux P, Bosco D,
Rouiller DG, Halban PA. Activation of NF-kappaB by extracellular matrix
is involved in spreading and glucose-stimulated insulin secretion of
pancreatic beta cells. J Biol Chem 2005;280:30630–30637
41. Norlin S, Ahlgren U, Edlund H. Nuclear factor-B activity in -cells is
required for glucose-stimulated insulin secretion. Diabetes 2005;54:125–
132
42. Zhang S, Liu J, MacGibbon G, Dragunow M, Cooper GJ. Increased
expression and activation of c-Jun contributes to human amylin-induced
apoptosis in pancreatic islet beta-cells. J Mol Biol 2002;324:271–285
43. Gouble A, Grazide S, Meggetto F, Mercier P, Delsol G, Morello D. A new
player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigen-
esis in transgenic mice. Cancer Res 2002;62:1489–1495
44. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky
N. Widespread changes in protein synthesis induced by microRNAs.
Nature 2008;455:58–63
45. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of
microRNAs on protein output. Nature 2008;455:64–71
46. Loffler D, Brocke-Heidrich K, Pfeifer G, Stocsits C, Hackermuller J,
Kretzschmar AK, Burger R, Gramatzki M, Blumert C, Bauer K, Cvijic H,
Ullmann AK, Stadler PF, Horn F. Interleukin-6 dependent survival of
multiple myeloma cells involves the Stat3-mediated induction of mi-
croRNA-21 through a highly conserved enhancer. Blood 2007;110:1330–
1333
47. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S,
Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates
tumor suppressor Pdcd4 and stimulates invasion, intravasation and me-
tastasis in colorectal cancer. Oncogene 2008;27:2128–2136
48. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH.
Programmed cell death 4 (PDCD4) is an important functional target of the
microRNA miR-21 in breast cancer cells. J Biol Chem 2008;283:1026–1033
49. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth.
Oncogene 2007;26:2799–2803
50. Hagerkvist R, Mokhtari D, Myers JW, Tengholm A, Welsh N. siRNA
produced by recombinant dicer mediates efficient gene silencing in islet
cells. Ann N Y Acad Sci 2005;1040:114–122
51. Olerud J, Johansson M, Lawler J, Welsh N, Carlsson PO. Improved vascular
engraftment and graft function after inhibition of the angiostatic factor
thrombospondin-1 in mouse pancreatic islets. Diabetes 2008;57:1870–1877
52. Sparre T, Larsen MR, Heding PE, Karlsen AE, Jensen ON, Pociot F.
Unraveling the pathogenesis of type 1 diabetes with proteomics: present
and future directions. Mol Cell Proteomics 2005;4:441–457
MicroRNAs AND IL-1–INDUCED -CELL FAILURE
986 DIABETES, VOL. 59, APRIL 2010 diabetes.diabetesjournals.org
